Objective: To examine the effect of co-supplementation with iron and vitamin C on antioxidant status, platelet function and low density lipoprotein oxidation in normal healthy volunteers. Design: The study was carried out with two groups of 20 subjects each acting as their own control, comparing presupplemention with postsupplemention. One group was supplemented with iron and the RDA level of vitamin C and the second group with iron and 260 mgad vitamin C. Setting: The International Antioxidant Research Centre, The Guy's, King's College and St Thomas's School of Biomedical Science, Guy's Campus, London. Subjects: Forty normal healthy volunteers, recruited from the staff of the Medical School and Hospital in which two volunteers withdrew during the study. Interventions: Subjects in both studies were randomly assigned to one of two groups (5 males and 5 females group) and received supplements containing iron (14 mgad) and either 60 mgad (Group A) or 260 mgad (Group B) vitamin C for 12 wk. Blood samples were taken at 6 wk and 12 wk, and prior to supplementation and analysed for iron and antioxidant status (transferrin bound iron, vitamin C and E, and b-carotene levels) in both studies. Samples from the ®rst study were analysed for the susceptibility of LDL isolated from plasma to Cu 2 -induced oxidation and samples from the second for platelet function. Results: Transferrin-bound iron was signi®cantly increased (P`0.05) at 12 wk, in Group A subjects (from 14.9 AE 5.3 mmolal to 19.5 AE 2.3 mmolal; mean AE s.d.; n 19), whereas those in Group B showed a signi®cant increase (P`0.05) after 6 wk (from 15.8 AE 4.5 mmolal to 20.4 AE 6.6 mmolal; n 19) which decreased at 12 wk (16.3 AE 5.0 mmolal). Plasma total ascorbate signi®cantly increased from an initial level of 59.3 AE 21.3 mmolal to 87.6 AE 29.0 mmolal after 6 wk and 81.7 AE 11.4 mmolal after 12 wk following the Group B supplementation, but only after 12 wk in Group A (from 64.0 AE 24.8 mmolal to 77.2 AE 13.2 mmolal). Plasma a-tocopherol concentrations were signi®cantly increased after 6 wk and 12 wk with both levels of supplementation (from 24.2 AE 5.7 mmolal Group A and 23.4 AE 5.3 mmolal Group B to 26.3 AE 5.5 mmolal and 25.7 AE 4.7 mmolal respectively at 12 wk). The mean lag phase to oxidation of low density lipoprotein (LDL) was signi®cantly increased in subjects in Group B after 12 wk ingestion of iron and 260 mg vitamin C (from 80.0 AE 14.8 min to 97.2 AE 16.9 min; n 9). Platelet sensitivity to ADP-induced aggregation was signi®cantly decreased (P`0.05) by 12 wk in Group A (from EC 50 2.3 AE 1.3 mM to 3.7 AE 2.2 mM; n 10), whereas those receiving higher vitamin C showed a signi®cant decrease (P`0.05; from EC 50 1.9 AE 0.6 mM to 3.1 AE 1.8 mM) after 6 wk which subsequently increased towards presupplemental levels (2.6 AE 1.6 mM). Platelets from the latter subjects showed a signi®cant reduction in ADP-induced ATP secretion at both 6 wk and 12 wk. Conclusion: The results show modest bene®cial effects on LDL oxidation and platelet function following supplementation with iron and vitamin C. No evidence for pro-oxidant effects was observed. Sponsorship: This work was funded by the Ministry of Agriculture, Fisheries and Food (AN 0513).
Introduction
Free radical-induced oxidative damage has been linked to the development of a range of pathologies such as cancers (Eichholzer et al, 1996; Pandely et al, 1995) and heart disease (reviewed in Rice-Evans & Bruckdorfer, 1992; Klatt & Esterbauer, 1996) . Although dietary studies have led to the attractive proposition that the intake of antioxidants may provide health bene®ts and protection against oxidative damage (Block, 1992; Enstrom et al, 1992; Gey et al, 1993; Knekt et al, 1994; Diplock, 1994; Ocke et al, 1995) . The general use of vitamin C supplements as bene®cial to health has been disputed (Herbert, 1994; Rehman et al, 1998; Podmore et al, 1998) . The latter reporting that dietary supplementation with 500 mgad for 6 wks caused changes in DNA base damage oxidation products in human lymphocytes, such that while levels of 8-oxoguanine decreased, levels of 8-oxoadenine increased, suggesting a possible risk factor for cancer. Furthermore, Rehman et al (1998) supplementing healthy volunteers with 14 mgad of Fe and either 60 mgad or 260 mgad of vitamin C also reported changes in DNA base damage oxidation products with both levels of supplements, such that total DNA base damage oxidation products increased after 6 wk. However, levels of total oxidation products returned to approximately initial levels after 12 wk supplementation.
One of the suggested complications arising from the ingestion of supplemental doses of vitamin C is the possibility that the vitamin itself would lead to the exacerbation of free radical damage rather than its amelioration (Herbert, 1994) . It has been suggested that vitamin C may not only increase the bioavailability of iron (Crawford, 1995) resulting in potentially more free radical generation, but might also participate in such chemistry itself through redox cycling of iron, generating a pro-oxidant environment (Halliwell & Gutteridge, 1990; Herbert et al, 1996) , as has been shown in vitro. However, a recent detailed review of the evidence suggested no clear support for the concept of pro-oxidant interactions between ascorbate and iron in vivo (Halliwell, 1996) .
In the normal healthy body, iron is sequestered and not readily available to catalyse free radical reactions (Halliwell & Gutteridge, 1990; Fairweather-Tait, 1993; McCord, 1996) . However, there are several clinical examples in which high levels of endogenous iron may occur, associated with depleted levels of plasma vitamin C, namely, in thalassemia (Cohen et al, 1981) , in haemochromatosis (Young et al, 1994) , and in iron overload in Bantu tribesman (Nienhuis, 1981) . Supplementation with vitamin C in these cases has been reported to produce deterioration in left ventricular function (Nienhuis, 1981) , and rapid progression of conditions such as congestive cardiomyopathy, haemochromatosis (McLaren et al, 1982) and haemolytic diseases, for example, paroxysmal nocturnal hemoglobinuria (Iwamoto et al, 1994 ) and glucose-6-phosphate dehydrogenase de®ciency (Campbell et al, 1975) . Also high levels of stored iron are associated with an increased risk of myocardial infarction in Finnish men (Salonen et al, 1992) .
Little is known about the antioxidantapro-oxidant effects of vitamin C with iron co-supplementation in the non-de®cient non-overload situation. Other authors have suggested that, outside of speci®c clinical conditions related to iron overload, ascorbic acid supplementation has no adverse effects in normal populations (Diplock, 1995; Bendich & Langseth, 1995) . Earlier studies by us and others using tissue culture (Collis et al, 1996) and animal models Cadenas et al, 1994; Collis et al, 1997) have failed to ®nd any deleterious effects of iron and vitamin C co-supplementation. This study addresses the question as to whether dietary co-supplementation of iron with vitamin C in normal healthy subjects can lead to deleterious effects in biochemical markers of oxidative stress related to cardiovascular disease. Since previous studies have shown a link between antioxidant levels and oxidative stress in platelet function (Salvemini et al, 1989; Salonen et al, 1992; Iuliano et al, 1992 Iuliano et al, , 1994 Violi et al, 1993; Calzada et al, 1997) and in the susceptibility of isolated plasma LDL to oxidation ex vivo (Esterbauer, 1989), we have examined parameters of both platelet function, aggregability and ATP release, and LDL oxidation.
Methods

Study Protocol
Subjects. Forty healthy volunteers (20 men, 20 women) aged between 21 and 45 y (30.3 AE 6.28 y; mean age AE s.d.) participated in the study. There were no signi®cant differences between the groups with respect to age and body mass index. Overall body mass index was 23.9 AE 3.86 kgam 2 . Exclusion criteria for the subjects included smoking, high alcohol intake (males b 21 unitsawk or female b 14 unitsawk), consumption of vitamin and mineral supplements other than those used in the study, pregnancy, oral contraceptives or drugs such as antihistamines, antibiotics, anti-in¯ammatories or aspirins which interfere with platelet function for a period of two weeks prior to the commencement of the study and during its course.
Study Design. The study was carried out in two similar parts with a total of 40 subjects. In each part of the study, subjects were randomly assigned to one of two groups (5 males and 5 females group) and all the subjects received proprietary brand (Boots Company, Nottingham, UK) vitamin and iron supplements containing 14 mg of iron (as ferrous sulphate) co-supplemented with either 60 mg vitamin C (as ascorbic acid) (Group A) or 60 mg vitamin C and an additional 200 mg vitamin C (total vitamin C, 260 mg) (Group B) per day for 12 wks. Blood samples were taken on three occasions, before supplementation started, after 6 wks and 12 wks supplementation. These samples were analysed for iron and antioxidant status (transferrin bound iron, vitamin C and E, and b-carotene levels) in both studies. In addition samples from the ®rst study were analysed for the susceptibility of LDL to oxidation and samples from the second study were analysed for platelet function (see below). The subjects fasted (including non-taking of supplements) for 12 h immediately before the blood samples were taken. The subjects were also required to complete a general health questionnaire and an 8 d food diary, which was assessed using the COMP-EAT dietary analysis computer programme. Compliance was determined by supplying a recorded excess of these supplements and counting the number of capsules returned by the subjects at the 6 wk and 12 wk visit. Compliance as judged by this means was equally high in all groups with an overall value of 99.5%.
Two subjects (one from each group) withdrew from the ®rst study, all the subjects completed the second study. Permission for the study was obtained from the Lewisham and North Southwark Committee on Ethical Practice.
Blood collection. Whole blood was collected by venepuncture and divided into aliquots in a variety of ways depending on the subsequent analysis to be performed. Blood samples for transferrin bound iron and unsaturated iron binding capacity (UIBC) were allowed to coagulate and the serum collected. Blood was also placed in heparinised tubes and either whole blood was taken for total hemoglobin analysis, or plasma samples separated by centrifugation for ascorbic acid, a-tocopherol and b-carotene analysis (both studies). Whole blood was also collected into acid-citrateadextrose containing 100 mM EDTA for Low Density Lipoprotein (LDL) preparation (®rst study) or 3.8% trisodium citrate anticoagulant (10 ml blooda1.1 ml anticoagulant) for platelet separation (second study).
Antioxidant status Ascorbic acid. Plasma samples were treated with 0.3 M trichloroacetic acid (TCA; 1 ml plasma: 4 ml TCA),
Iron and vitamin C co-supplementation M Yang et al centrifuged at 1500 g and the supernatant¯uid stored at 7 70 C. Total ascorbic acid levels were determined uorimetrically using a modi®cation of the method of Deutsch & Weeks (1965) . In brief, the TCA treated samples were oxidised with iodine and a complex formed with orthophenylenediamine (OPD). The resulting¯uorescence was read on a Shimadzu RF-1501¯uorimeter (excitation wavelength 348 nm; emission wavelength 423 nm). The concentration of ascorbic acid in the incubation mixtures was determined by comparison with previously prepared standards.
a-tocopherol and b-carotene. Plasma a-tocopherol and bcarotene levels were determined by high performance liquid chromatography (HPLC) (Rice-Evans et al, 1991) . Plasma samples were ®rst deproteinised with methanol (0.25 ml plasma: 1 ml methanol), the a-tocopherol and bcarotene extracted in 1 ml of hexane and centrifuged at 1500 g. The a-tocopherol and b-carotene content of the hexane supernatant¯uid was measured by normal phase HPLC (Novapak silica column: 4 mM, 3.9 6 156 mm). The mobile phase consisted of 8% methyl tert-butyl ether and 92% hexane pumped at a¯ow rate of 1 mlamin. Detection was performed¯uorimetrically (excitation wavelength 295 nm; emission wavelength 340 nm). Quanti®cation was obtained by comparison with previously prepared standards. d-Tocopherol was used as the internal standard.
Iron status Total hemoglobin. Heparinised whole blood samples were treated with Drabkins Reagent (Randox Hemoglobin Assay Kit, Randox Laboratories Ltd, UK) and the cyanmethemoglobin formed quanti®ed spectrophotometrically at 540 nm by comparison with standards.
Transferrin-bound iron and unsaturated iron binding capacity (UIBC). To determine the transferrin bound iron, ferric iron from serum samples was dissociated from the transferrin and simultaneously reduced using ascorbic acid. The ferrous iron was then complexed with ferene chromogen (Randox Serum IronaUIBC Assay Kit, Randox Laboratories Ltd, UK) and the chromophore formed was quanti®ed spectrophotometrically at 595 nm by comparison with previously prepared standards. UIBC was determined by adding a known amount of ferrous iron to saturate the unoccupied transferrin binding sites, quantifying the remaining free iron as described above for serum iron and subtracting this from the original total amount added. From the values obtained the Total Iron Binding Capacity (TIBC Transferrin bound Iron UIBC) and percent saturation of transferrin (100 6 Transferrin bound IronaTIBC) were also calculated.
Platelet studies Platelet preparation. After collection and anticoagulation, blood was immediately centrifuged at 200 g for 17 min at 20 C to separate platelet-rich plasma (PRP). The PRP was removed and the remaining blood recentrifuged at 1500 g for 20 min at 20 C and the upper plasma layer removed to obtain platelet-poor plasma (PPP).
Platelet aggregation. Platelet aggregation was measured in PRP according to the turbidometric method of Born (1962) using a Payton lumi-aggregometer. Adenosine diphosphate (1 ± 5 mM) was used to induce aggregation and the extent of platelet aggregation was expressed in terms of percentage change in light transmission, 4 min after the addition of the agonist. A dose response curve (%aggregation vs agonist concentration) was constructed for each subject per visit (Initial, 6 wk and 12 wk) and the ADP concentration producing 50% aggregation (EC 50 ) calculated.
The number of platelets in the PRP was not normalised before aggregation studies because each subject acted as their own control and platelet numbers were found to be similar on all three visits.
Inhibition of platelet aggregation. Inhibition of ADPinduced platelet aggregation by PGE 1 in PRP samples was determined. Platelets were preincubated with PGE 1 (0 ± 40 ngaml) and a threshold concentration of ADP added. A dose-inhibition curve was constructed (%aggregation vs inhibitor concentration) and the concentration of PGE 1 causing 50% inhibition of ADP-induced platelet aggregation (IC 50 ) was calculated.
ATP secretion. ADP-stimulated ATP release by platelets was measured using luciferin-luciferase luminescence. In brief, luciferin-luciferase (11 ml) was added to 100 ml PPP followed by ADP (5 mM). Once aggregation was complete, the luminescence channel was calibrated by adding ATP (concentration dependent on previously determined sensitivity of platelets).
Low density lipoprotein (LDL) oxidation LDL was prepared by initial ultracentrifugation at 100 000 g for 2 h in saline, followed by 2 h ultracentrifugal otation in NaBr density solution (1.154 gaml and 1.063 gaml) at 400 000 g and subsequent dialysis in phosphate buffered saline (10 mM phosphatea154 mM NaCl, pH 7.4, containing 100 mM EDTA) at 4 C (Chung et al, 1980) . The LDL so isolated was passed through a 0.2 mm pore size ®lter (Millipore), and used within 24 h of preparation.
The oxidation of LDL was carried out by a modi®cation of the method described by Esterbauer et al (1989) . Oxidation was initiated by adding Cu 2 (®nal concentration 1.66 mM) to LDL (®nal concentration 62.5 mg LDL proteinaml) and the increased formation of conjugated dienes was monitored for 4 h at 30 C by measuring the increase in absorbance between 210 ± 300 nm. Control samples for the oxidation were subjected to the same incubation conditions in the absence of Cu 2 .
Statistics
Results are expressed as mean AE s.d. except in Figure 2 . In the ®rst part of the study, the lag phase to conjugated diene formation was determined, and in the second the effect of supplementation on platelet aggregation. For all other parameters the data from both studies were pooled. Statistical analysis was performed using Microsoft Excel. All tests were two-tailed and P values`0.05 for t in differences between two values were considered to be signi®-cantly different.
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Results
Dietary analysis
Analysis of the subject's nutritional intake (without supplementation) from their dietary diaries during both studies is shown in Table 1 . The presupplemental daily amounts of iron ingested varied by a factor of six from the minimum to the maximum and those of vitamin C by a factor of ten.
Iron
Hemoglobin. Supplementation with 14 mg iron and either 60 (Group A) or 260 mg vitamin (Group B) had no signi®cant effect on the subjects' hemoglobin concentrations at either 6 wk (14.4 AE 1.8 gadl Group A and 14.6 AE 1.3 gadl Group B) or 12 wk (15.0 AE 17 gadl Group A and 15.0 AE 1.5 gadl Group B) of supplementation compared to the initial presupplemental concentrations of 14.6 AE 2.0 gadl for Group A and 14.5 AE 2.4 gadl for Group B (n 19 in each Group).
Transferrin-bound iron. Determination of transferrinbound iron showed that, in Group A the mean concentration of transferrin-bound iron increased to a concentration that was signi®cantly different from that of the initial value (P`0.05) after 12 wk (Figure 1 ). On the other hand, subjects from Group B showed a signi®cant increase (P`0.05) in transferrin-bound iron after 6 wk which subsequently decreased towards initial concentrations after 12 wk (Figure 1 ). There was a tendency for the mean UIBC concentrations to decrease over the 12 wk period but these changes were not signi®cantly different from the initial values of 38.0 AE 8.9 mmolal, Group A and 40.5 AE 11.8 mmolal, Group B (n 19 in each Group). The percent saturation of transferrin showed a similar trend to those of the transferrin-bound iron, Group A increased from 24.5 AE 9.5% saturation to 36.0 AE 15.4 after 6 wk and 34.7 AE 9.8 after 12 wk, while Group B started at 32.4 AE 10.5 and went to 35.7 AE 8.2 to and back to 32.0 AE 4 8.1 after 12 wk. The higher the initial basal values of transferrin-bound iron the lower the extent of any further rise, in general. For example, in Group B, there was an inverse relationship (r 7 0.706, n 19, P`0.05) between the initial transferrin-bound iron and the change in bound iron after 6 wk. The initial transferrin-bound iron intercept was 17.4 mmolal and the slope 7 1.4.
Antioxidants
Plasma ascorbate. Supplementation with iron and either of the vitamin C concentrations studied (60 mgad or 260 mgad) increased the plasma ascorbate concentrations (Table 2 ). This increase was signi®cantly different from the initial presupplemental concentration after 6 wk and 12 wk (P`0.05) in Group B. Subjects receiving 60 mgad of vitamin C iron also showed an increase, which although apparent after 6 wk, did not show a statistically signi®cant difference until 12 wk (P`0.05). Furthermore, similarly to transferrin bound iron there was an inverse relationship between existing plasma levels and any further rise in plasma concentration after supplementation. For example in the case of subjects on 60 mgad vitamin C iron, the correlation coef®cient for the relationship between the initial plasma vitamin C concentration and the change in concentration after 6 wk on 60 mgad vitamin C iron was r 7 0.8553 (n 19, P`0.05). Further the regression equation gave the initial plasma vitamin C intercept as 73.5 mmolal and the slope 7 1.02. Mean values AE s.d. are shown; n 38. CHO, carbohydrate. Vitamin E was calculated as a-tocopherol equivalents, that is other forms of tocopherol were converted to the equivalent amount of a-tocopherol having the same level of activity and includes g-tocopherol. Vitamin C includes both ascorbic acid and dehydroascorbic acid. Iron includes haem and nonhaem iron. Data obtained from COMP-EAT dietary analysis computer programme. (Holland et al, 1991) . 
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Plasma a-tocopherol and b-carotene. Supplementation with iron with both 60 mg and 260 mg vitamin C produced a signi®cant increase (P`0.05) in plasma a-tocopherol concentration after 6 wk (Table 2) . Furthermore, although the mean plasma concentration decreased slightly compared to that at 6 wk, in both cases the a-tocopherol concentrations were still signi®cantly higher at the end of 12 wk than the initial presupplemental plasma concentrations (Table 2) . Although the plasma a-tocopherol levels were not lipid corrected, analysis of the subjects' dietary diaries showed that there was no statistically signi®cant change (P`0.05; paired t-test) in the intake of vitamin E, total fats, polyunsaturated fats, monounsaturated fats or saturated fats for either Group A or Group B when comparing the dietary intake at 6 wks with that at 12 wks. Supplementation had no signi®cant effect on b-carotene concentration of the plasma at either 6 wk or 12 wk of supplementation compared to the presupplemental concentrations (Table 2 ). Again this suggests that the lipid levels did not change in the study as most of the b-carotene is carried in the LDL particles.
Oxidative damage LDL oxidation. In the ®rst part of the study the lag phase to conjugated diene formation was determined. There was a tendency that was not statistically signi®cantly different at P`0.05) for the mean duration of the lag phase to increase from the initial duration of 82 AE 9.2 min to 91.3 AE 19.8 min (n 9) after 12 wk on supplementation with iron 60 mgad vitamin C and from 80 AE 14.8 min to 97.2 AE 16.9 min (n 9) on iron 260 mgad vitamin C. The latter lag phase was signi®cantly different from the presupplementation one (P`0.05).
Platelet aggregation. Platelet function has been suggested to be sensitive to levels of free radicals (Salvemini et al, 1989; Iuliano et al, 1994) and the supplementation of healthy volunteers with antioxidant nutrients has been shown to decrease their platelet aggregation responses to, for example ADP (Calzada et al, 1997) . In this study ADP induced aggregation of platelets in a concentration-dependent manner (Figure 2) . Supplementation resulted in a decrease in sensitivity to ADP-induced aggegation. This was seen as an increase in the concentration of ADP, expressed as EC 50 , required to induce platelet aggregation. The EC 50 of subjects in Group A showed an increase from the initial value of 2.3 AE 1.3 mM to 3.0 AE 2.0 mM (n 10) after 6 wk and a statistically signi®cant increase (P`0.05; vs initial value) to 3.7 AE 2.2 mM at 12 wk. Furthermore, the increase in EC 50 of Group B was signi®cantly different (P`0.05) from the initial value (1.9 AE 0.6 mM) after 6 wk (3.1 AE 1.8 mM), but not after 12 wk (2.6 AE 1.6 mM).
Changes were also found in the amount of ATP released by the platelets. In Group A, the mean concentration of ATP secreted decreased from 0.53 AE 0.33 mM to 0.36 AE 0.30 mM after 6 wk and to 0.32 AE 0.30 mM after 12 wk. However, these reductions were not statistically signi®cant (P b 0.05). A similar trend was observed in Group B, but this time the decrease was statistically signi®cant compared to initial values after both 6 wk and 12 wk (Figure 3a ).
There were no signi®cant effects on the IC 50 of PGE 1 required to inhibit ADP-induced aggregation in either of the supplemented groups at 6 wk or 12 wk (Figure 3b ).
Discussion
In this study an increased intake of iron, with two levels of ascorbic acid, increased the levels of transferrin-bound iron but not of hemoglobin, and it therefore seems likely that some of the Fe was absorbed. Furthermore, the increase in transferrin-bound iron was affected by the level of vitamin C supplementation. The lower level of supplementation (60 mgad) produced a steady increase which was statistically signi®cant after 12 wk, whereas the higher level (260 mgad) produced a statistically signi®cant increase after 6 wk which decreased towards initial levels after 12 wk. Ascorbic acid has the potential to facilitate the gastrointestinal absorption of non-haem iron (Cook et al, 1984; Hallberg et al, 1986) with the potential of converting Fe 3 to Fe 2 (Baird et al, 1974; Levine, 1986) . However, although ascorbic acid can increase iron levels in this way, the duration of the effect may be dependent on vitamin C intake, and vitamin C has been shown to have a lesser effect on iron metabolism in the longer term (Cook et al, 1984; Hunt et al, 1994) .
Total ascorbate levels in the plasma were increased as a consequence of supplementation. The extent of the increase was dependent on the initial plasma concentration, that is the lower the initial concentration the greater the increase, with a mean plasma concentration of 77.4 AE 13.2 mmolal after supplementation of 60 mgad and 81.7 AE 11.4 mmolal at 260 mgad after 12 wk supplementation. This has been observed in previous human studies with vitamin C supplementation; for example, Calzada et al (1997) reported a level of 81.8 AE 4.2 mmolal after a supplementation of 250 mgad for 8 wk and Jacob et al (1996) found approximately 75 mmolal with a supplementation of 495 mgad for Iron and vitamin C co-supplementation M Yang et al 6 wk. These observations con®rm the existence of a homeostatic regulation at these concentrations, as described previously for example by Kallner et al (1979) and Levine et al (1996) . It is worth noting that the basal levels of vitamin C suggested a generally good state of vitamin C nutrition in these subjects.
As well the plasma levels of antioxidants, we investigated other markers of ongoing free radical activity that may be relevant to cardiovascular disease. Iron and free radicals have both been implicated in regulation of platelet function (Salvemini et al, 1989; Iuliano et al, 1994) and studies on platelets from iron-de®cient and iron-overloaded patients have suggested an inverse relationship between platelet vitamin C concentration and iron status (Chatterjea et al, 1980) . Arachidonic acid is released during platelet activation and is a substrate for endoperoxidases and thromboxases, whose products stimulate platelet aggregation (Siess, 1989) ; iron plays a critical role in the oxidation of arachidonic acid (Rao, 1978) . Increased levels of lipid hydroperoxides that may derive from free radical reactions can stimulate cyclooxygenase which leads to an increase in concentration of the pro-aggregant thromboxane A 2 (Kulmacz & Lands, 1983) , and inhibition of prostacyclin synthase which catalyses the formation of prostacyclin, an inhibitor of platelet aggregation (Bunting et al, 1976) . The results of this present study show a signi®cant decrease in the aggregation responses of platelets to ADP and a decrease in the ability of stimulated platelets to secrete ATP following supplementation. However, platelet sensitivity to inhibition of ADP-induced aggregation by PGE 1 was unaffected. These results from the present study suggest that supplementation with iron and vitamin C did not have a pro-oxidant effect which would have tended to increase platelet sensitivity. On the contrary, a decrease in the parameters measured was observed which is highly suggestive of an antioxidant effect of the supplementation. Vitamin C has been reported in human studies both to decrease platelet aggregation in vivo (Cordova et al, 1982) and to regenerate vitamin E in platelets (Chan et al, 1991) which might in turn be expected to reduce platelet aggregation (Steiner, 1978) as was recently shown by Calzada et al (1997) . In a double-blind, placebo-controlled human trial (Calzada et al, 1997) vitamin C supplementation (250 mgad for 8 wk) by itself had no signi®cant effect on platelet function, although a tendency towards decreased platelet aggregability and an increased sensitivity to PGE 1 inhibition was observed. These authors regarded the mean initial plasma vitamin C levels of their subjects as relatively high (65 AE 6 mmolal) and, since the plasma vitamin C level increased by only 26% after supplementation, it was proposed that this was insuf®cient to have any signi®cant on platelet sensitivity. Furthermore there were no changes in plasma vitamin E or b-carotene concentration following supplementation with vitamin C. The differences in the results between the study reported here and our earlier study (Calzada et al, 1997 ) using vitamin C alone (250 mgad) suggest that the effects of iron and vitamin C co-supplementation on platelet sensitivity may not be entirely due to vitamin C by itself, and may involve some interactions between iron and ascorbic acid; the role of iron remains to be elucidated.
The exact causes of initiation and propagation of free radical-induced LDL oxidation in vivo are unknown, although transition metals and haem proteins will readily amplify peroxidation processes in a catalytic fashion in vitro . An increase in endogenous free radical activity would have the effect of both reducing the levels of antioxidants and increasing the seeding of peroxides in LDL. If either of these processes occurred following supplementation with iron and vitamin C, one would expect the susceptibility in vitro to Cu 2 oxidation to be raised. This change in susceptibility would not, of course, imply increased predisposition to atherosclerosis, but might indicate decreased antioxidant status of the LDL andaor increased levels of endogenous peroxides within the LDL particles. In fact there was a tendency for the lag phase to increase on supplementation, which was statistically signi®cant after 12 wk supplementation for the given high vitamin C and iron doses. This effect of ascorbic acid acting as an antioxidant to lipids is similar to that reported by Berger et al (1997) , who observed a protective effect of ascorbic acid in the plasma of iron overloaded adults and premature infants. However, the effects could also be due to increases in the level of vitamin E contained in LDL.
Conclusions
This study on normal healthy human volunteers, showed that co-supplementation with iron and either low, or high, levels of vitamin C increased plasma vitamin C levels and iron levels as indicated by transferrin bound iron. These increases depended on the initial level of these substances in the plasma and the concentration of vitamin C given, with apparent homeostatic mechanisms regulating the uptake at the upper limits of plasma vitamin C concentration. No indication of persistent increased endogenous free radical activity with these combinations of supplements was found. On the contrary increased levels of antioxidants Iron and vitamin C co-supplementation M Yang et al with iron, decreased susceptibility of LDL to oxidation and decreased sensitivity of platelets to aggregating stimuli (both markers relevant to the development of cardiovascular disease), all mitigate against the suggestion that iron and vitamin C-driven activity over a 12 wk supplementation regimen is a relevant mechanism for oxidative damage in human subjects in vivo. This is distinct from our investigations on the effects of co-supplementation of vitamin C together with iron on white cell DNA bases (which formed part of the present study, but is described elsewhere; Rehman et al, 1998) . These studies showed that, although at the end of 12 wk supplementation there was no apparent effect on DNA base damage products, there was an increase after 6 wks (in subjects with initial plasma vitamin C levels at the higher end of the normal range) which returned to basal levels with continued supplementation up to 12 wk. While the enhancement at 6 wk is disturbing in view of the common use of such supplements and the potential for mutagenicity, the attentuation of this effect after prolonged supplementation suggested a potentially bene®cal effect, possibly through up-regulation of DNA repair enzymes.
